omeprazole

(redirected from Omez)
Also found in: Dictionary, Thesaurus.

omeprazole

 [o-mep´ra-zōl]
a proton pump inhibitor, used in treatment of dyspepsia, gastroesophageal reflux disease, disorders of gastric hypersecretion, and peptic ulcer, including that associated with Helicobacter pylori infection; administered orally.

omeprazole

/omep·ra·zole/ (o-mep´ra-zōl) an inhibitor of gastric acid secretion used in the treatment of dyspepsia , gastroesophageal reflux disease, disorders of gastric hypersecretion, and peptic ulcer, including that associated with Helicobacter pylori infection.

omeprazole

(ō-mĕp′rə-zōl′)
n.
A proton pump inhibitor drug, C17H19N3O3S, that suppresses gastric acid secretion and is used for the treatment of duodenal and gastric ulcers and gastroesophageal reflux disease.

omeprazole

Prilosec® Therapeutics A proton pump inhibitor used to manage GERD; heartburn; erosive esophagitis; maintenance of healed erosive esophagitis; short-term management of active duodenal ulcer and active benign gastric ulcer, and for certain hypersecretory conditions; combined with clarithromycin to eradicate H pylori associated with duodenal ulcers. See GERD, Helicobacter pylori. Cf H2 blockers.

omeprazole

The first of the class of proton pump inhibitor drugs used to control the production of stomach acid and treat stomach and duodenal ulcers and especially the ZOLLINGER-ELLISON SYNDROME. OMEPRAZOLE can be effective in cases that have failed to respond to H-2 receptor blocker drugs such as RANITIDINE. The drug is long-acting and need only be taken once a day. A brand name is Losec.

omeprazole (ōmep´rəzōl´),

n brand name: Prilosec;
drug class: antisecretory compound;
action: suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in the gastric parietal cell;
uses: gastroesophageal reflux disease (GERD), severe erosive esophagitis, pathologic hypersecretory conditions (Zollinger-Ellison syndrome, mastocytosis, multiple endocrine adenomas).

omeprazole

a substituted benzimidazole that is a long-acting inhibitor of gastric ATPase; used in the treatment of gastric ulcers.
References in periodicals archive ?
YoY growth of 44% driven by key brands of Omez, Nise, Ketorol and Cetrine.
This growth was primarily driven by growth in key brands of Omez, Stamlo, Stamlo Beta, Razo and Atocor and the launch of Reditux.
This increase was driven by performance of key brands of Nise, Omez and Cetrine.
Nise and Omez performed exceptionally well with combined revenues of Rs 344 million during the quarter compared to Rs 163 million in Q3 FY05.
This was however offset by decline in revenues from our key brand of Omez.
The growth was driven primarily by the performance of the key brands of Omez, Keterol and Nise.
Omez, our brand of Omeprazole increased by 34% to Rs 624